[Anticholinergic treatment of Parkinson's disease (author's transl)].
Anticholinergic drugs retain their place even today in the treatment of Parkinson's disease in spite of the considerable success achieved by means of stereotactic surgery and substitution therapy with dopa or dopa derivatives. An investigation was made on 44 patients suffering from Parkinson's disease treated with the new anticholinergic drug, Sormodren (Knoll). Sormodren showed a selective action on the hyperkinetic and autonomic symptoms of this disease of the extrapyramidal system. Tolerance was good, no serious side effects being observed.
D000328:Adult; D000368:Aged; D055598:Chemical Phenomena; D002621:Chemistry; D002986:Clinical Trials as Topic; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010276:Parasympatholytics / Q000008:administration & dosage / Q000627:therapeutic use*; D010300:Parkinson Disease / Q000188:drug therapy* / Q000601:surgery; D013238:Stereotaxic Techniques
D010276:Parasympatholytics
Das anticholinergische Behandlungsprinzip des Morbus Parkinson